Pharmaceutical Companies

Under the agreement, Lilly will obtain exclusive worldwide rights, excluding South Korea, to develop, manufacture, and commercialise sonefpeglutide, a long-acting GLP-2 analogue.

The regulatory decision follows results from a Phase Ib study presented at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference and the 2026 International Scientific Congress on SMA Europe.

Established in 2022, the collaboration combines CytomX’s Probody masking technology with Regeneron’s Veloci-Bi bispecific antibody platform.

Through this arrangement, Pfizer aims to accelerate the identification and design of new therapeutic candidates, particularly in areas where traditional research methods have faced limitations.

Wegovy® pill is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist approved for weight management.

The funding will support three promising vaccine candidates being developed by Moderna, the University of Oxford in partnership with the Serum Institute of India, and the International AIDS Vaccine Initiative (IAVI).

Ascidian will lead target discovery and selected preclinical activities, while Lilly will oversee additional preclinical development, clinical research, manufacturing, regulatory activities, and global commercialization.

The agreement brings together Pfizer’s global expertise in clinical development, regulatory affairs, and commercialization with Innovent’s strengths in scientific discovery and early-stage oncology research.

Under the deal, Blackstone Life Sciences will provide up to US$800 million in exchange for low- to mid-single-digit tiered royalties on future zumilokibart sales for 15 years.

Health authorities estimate that approximately 20,000 babies are born with the condition each year, while nearly 30 percent of the population carries the sickle cell trait.